The antitumor efficacy of the PD-L1-targeted split fragments (ɑPD-L1-Neo2A + ɑPD-L1-Neo2B) was superior to that of the untargeted split fragments (Ctrl-Neo2A + Ctrl-Neo2B), as well as to that of the targeted and untargeted intact Neo-2/15 fusion proteins, resulting in extended survival and complete tumor clearance in two mice (Fig. 3b). The gene discussed is CD274; the disease is neoplasm.